Ronald S. Go

20.7k total citations · 2 hit papers
362 papers, 7.3k citations indexed

About

Ronald S. Go is a scholar working on Hematology, Genetics and Physiology. According to data from OpenAlex, Ronald S. Go has authored 362 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 136 papers in Hematology, 102 papers in Genetics and 84 papers in Physiology. Recurrent topics in Ronald S. Go's work include Multiple Myeloma Research and Treatments (67 papers), Histiocytic Disorders and Treatments (63 papers) and Chronic Lymphocytic Leukemia Research (50 papers). Ronald S. Go is often cited by papers focused on Multiple Myeloma Research and Treatments (67 papers), Histiocytic Disorders and Treatments (63 papers) and Chronic Lymphocytic Leukemia Research (50 papers). Ronald S. Go collaborates with scholars based in United States, Canada and Saudi Arabia. Ronald S. Go's co-authors include Alex A. Adjei, S. Vincent Rajkumar, Gaurav Goyal, Prashant Kapoor, John A. Lust, Morie A. Gertz, Shaji Kumar, Angela Dispenzieri, Francis K. Buadi and Robert A. Kyle and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ronald S. Go

325 papers receiving 7.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin

1999 562 citations Ronald S. Go et al. profile →
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

2012 481 citations Ken H. Young, Carlo Visco et al. profile →

Peers

Countries citing papers authored by Ronald S. Go

Since Specialization

Citations

This map shows the geographic impact of Ronald S. Go's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald S. Go with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald S. Go more than expected).

Fields of papers citing papers by Ronald S. Go

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald S. Go. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald S. Go. The network helps show where Ronald S. Go may publish in the future.

Co-authorship network of co-authors of Ronald S. Go

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald S. Go. A scholar is included among the top collaborators of Ronald S. Go based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald S. Go. Ronald S. Go is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PD-L1 expression and response to immune checkpoint inhibitor therapy in malignant histiocytic neoplasms 2025 ·Leukemia & lymphoma ·Aishwarya Ravindran, Liuyan Jiang, Gordon Ruan, Surendra Dasari, Jithma P. Abeykoon, Saurabh Zanwar, (unknown), (unknown), Jonathan McConathy, N. Nora Bennani, Ronald S. Go, Gaurav Goyal, Karen L. Rech	0
2	Central nervous system crystal‐storing histiocytosis: A case report and literature review 2024 ·European Journal of Neurology ·Nabeela Nathoo, Daniel P. Larson, Yong Guo, Caterina Giannini, Claudia F. Lucchinetti, Ivana N. Micallef, Karen L. Rech, Dragan Jevremović, Daniel H. Lachance, Jithma P. Abeykoon, Ronald S. Go, W. Oliver Tobin	1
3	Efficacy of Small Molecule Kinase Inhibitors in Histiocytic Neoplasms with Non-BRAFV600E Mutations: Concordance of Pre-Clinical Predictions to Clinical Responses 2024 ·Blood ·(unknown), (unknown), N. Nora Bennani, Gaurav Goyal, Aishwarya Ravindran, Karen L. Rech, Gordon Ruan, Mithun Vinod Shah, (unknown), Saurabh Zanwar, Jithma P. Abeykoon, Ronald S. Go	1
4	Hypofractionated Radiation Therapy for Subcutaneous Rosai-Dorfman Disease: A Case Report 2024 ·Advances in Radiation Oncology ·(unknown), William G. Breen, Ronald S. Go, (unknown), Scott C. Lester	0
5	Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis 2024 ·American Journal of Hematology ·Gordon Ruan, Saurabh Zanwar, Aishwarya Ravindran, (unknown), Jithma P. Abeykoon, Antonious Hazim, Jason R. Young, Mithun Vinod Shah, N. Nora Bennani, Liuyan Jiang, Diana Morlote, Karen L. Rech, Gaurav Goyal, Ronald S. Go	9
6	Spectrum of second primary malignancies and cause-specific mortality in pediatric and adult langerhans cell histiocytosis 2023 ·Leukemia Research ·Gaurav Goyal, (unknown), Joshua Richman, Jithma P. Abeykoon, Diana Morlote, Ronald S. Go, Smita Bhatia	7
7	Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval 2021 ·Leukemia Research ·John W. Thomas, Omer Jamy, Mithun Vinod Shah, Pankit Vachhani, Ronald S. Go, Gaurav Goyal	3
8	Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival 2021 ·American Journal of Hematology ·Antonious Hazim, Gordon Ruan, Marie Hu, Aishwarya Ravindran, Karen L. Rech, Jason R. Young, Christian W. Cox, Jithma P. Abeykoon, Caleb Scheckel, Robert Vassallo, Jay H. Ryu, W. Oliver Tobin, Matthew J. Koster, N. Nora Bennani, Mithun Vinod Shah, Gaurav Goyal, Ronald S. Go	10
9	Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis 2020 ·Blood Cancer Journal ·(unknown), Amit Kulkarni, Beibei Xu, Haitao Chu, Taxiarchis Kourelis, Ronald S. Go, Michael Wang, Veronika Bachanová, Yucai Wang	26
10	Financial conflicts of interest among National Comprehensive Cancer Network clinical practice guideline panelists in 2019 2020 ·Cancer ·Aakash Desai, (unknown), Ronald S. Go, (unknown)	12
11	Category of evidence and consensus underlying National Comprehensive Cancer Network guidelines: Is there evidence of progress? 2020 ·International Journal of Cancer ·Aakash Desai, Ronald S. Go, (unknown)	12
12	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis 2020 ·American Journal of Hematology ·Surbhi Sidana, Eli Muchtar, M Hasib Sidiqi, Dragan Jevremović, Angela Dispenzieri, Wilson I. Gonsalves, Francis K. Buadi, Martha Q. Lacy, Suzanne R. Hayman, Taxiarchis Kourelis, Prashant Kapoor, Ronald S. Go, Rahma Warsame, Nelson Leung, S. Vincent Rajkumar, Robert A. Kyle, Morie A. Gertz, Shaji Kumar	32
13	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients 2019 ·American Journal of Hematology ·Abdullah S. Al Saleh, M Hasib Sidiqi, Angela Dispenzieri, Prashant Kapoor, Eli Muchtar, Francis K. Buadi, Rahma Warsame, Martha Q. Lacy, David Dingli, Nelson Leung, Wilson I. Gonsalves, Taxiarchis Kourelis, Morie A. Gertz, Ronald S. Go, Robert A. Kyle, S. Vincent Rajkumar, Shaji Kumar	11
14	Clinical Associations, Treatment, and Outcomes of Renal-Limited Thrombotic Microangiopathy 2018 ·Blood ·Elias S. Saba, (unknown), Ronald S. Go, Nelson Leung, Meera Sridharan	7
15	Immune-Mediated Hematologic Complications of Checkpoint Inhibitors: A Review of the Literature 2018 ·Blood ·(unknown), Irbaz Bin Riaz, Ronald S. Go	1
16	Florid dermatopathic lymphadenopathy—A morphological mimic of Langerhans cell histiocytosis 2018 ·Clinical Case Reports ·Aishwarya Ravindran, Gaurav Goyal, (unknown), Ronald S. Go, Karen L. Rech	9
17	A follow‐up on desiderosmia (olfactory craving), a novel symptom associated with iron deficiency anemia 2017 ·American Journal of Hematology ·(unknown), Wayne A. Bottner, Aishwarya Ravindran, Ramona S. DeJesus, Ronald S. Go	3
18	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation 2015 ·Nephrology Dialysis Transplantation ·Nelson Leung, Shaji Kumar, Siobhán Glavey, Angela Dispenzieri, Martha Q. Lacy, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Prashant Kapoor, Steven R. Zeldenrust, Stephen J. Russell, John A. Lust, William J. Hogan, S. Vincent Rajkumar, Dennis A. Gastineau, Taxiarchis Kourelis, Yi Lin, Wilson I. Gonsalves, Ronald S. Go, Morie A. Gertz	22
19	Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma 2013 ·Journal of Clinical Pathology ·Emil Frei, Carlo Visco, Zijun Y. Xu‐Monette, S Dirnhofer, Karen Dybkær, Attilio Orazi, Govind Bhagat, Eric D. Hsi, J. Han van Krieken, Maurilio Ponzoni, Ronald S. Go, Miguel Á. Piris, Michael Møller, Ken H. Young, Alexandar Tzankov	19
20	ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602) 2013 ·Clinical Cancer Research ·Ronald S. Go, Sandra J. Lee, Donghoon Shin, Steven M. Callister, Dean A. Jobe, Robert M. Conry, Ahmad A. Tarhini, John M. Kirkwood	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact